The U.S. medical marijuana market is anticipated to witness robust growth by the end of 2027 owing to its legalization and high usage for the treatment of various ailments such as nausea, pain management, anorexia, and seizures among many others.

Today, almost every U.S. state has laws around the use of medical marijuana, in fact, more than two thirds of the states in the U.S., as well as the District of Columbia, have legalized it for medical purposes. Now, ore states are considering to pass bills to do the same thing; as of 14th April 2021, around 17 states, two territories, and the District of Columbia, have passed legislation to legalize cannabis for adult use.

Medical marijuana is basically a plant-based drug, derived from the Cannabis indica or Cannabis sativa species. It contains three main active medicinal compounds, which includes CBN, CBD, and THC. Medical marijuana mainly utilizes the plant or the various marijuana chemicals in it to treat numerous conditions or diseases.

The U.S. medical marijuana market is bifurcated in terms of application, route of administration, distribution channels, and zones.

With respect to application, the overall market is segmented into anorexia, seizures, pain management, nausea, muscle spasms, and others. Nausea segment is expected to reach a valuation of over $754.0 million by the end of 2027. One of the biggest known patient groups, that consume medical marijuana for the suppression vomiting and nausea, are cancer patients that are undergoing chemotherapy treatments.

There are two chemically pure medications that are primarily based on marijuana compounds that have been approved for medical use across the U.S. First, Nabilone or Cesamet?(R) is known as a synthetic cannabinoid that acts like THC. It can usually be taken by mouth to treat nausea as well as vomiting, mainly caused by chemotherapy when other drugs have failed to work.

Second, Dronabinol, which is a gelatin capsule comprising of delta-9-THC (tetrahydrocannabinol) that is FDA approved to treat symptoms of nausea and vomiting caused by poor appetite and weight loss in patients with AIDS and cancer chemotherapy.

With respect to route of administration, the U.S. medical marijuana market is classified into topical, oral, and inhalation. In 2020, the oral route of administration segment accounted for more than 21.3% of the market share, and is forecasted to progress at rapid pace over the projected period.

Based on distribution channel, the U.S. medical marijuana market is divided into online and dispensaries. In 2020, the online segment accounted for more than $2.9 billion valuation, and will witness strong growth through the course of the analysis time period.

In terms of the zones, the South Atlantic zone is projected to witness a CAGR of more than 10.1% over the projected time period attributing to escalating consumer demand.